These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31941506)

  • 1. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
    Connell CM; Brais R; Whitaker H; Upponi S; Beh I; Risdall J; Corrie P; Janowitz T; Jodrell DI
    BMC Cancer; 2020 Jan; 20(1):38. PubMed ID: 31941506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
    Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
    Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma.
    Aurilio G; Macarulla T; Ramos JF; Fazio N; Nolè F; Iglesias C
    Tumori; 2011; 97(2):239-42. PubMed ID: 21617724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
    Elias A; Chatzizacharias NA; Xanthis A; Corrie P; Davies S; Brais RJ; Jamieson NV; Praseedom RK; Huguet E; Harper SJF; Jah A
    Medicine (Baltimore); 2015 Feb; 94(6):e499. PubMed ID: 25674740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy - a case report].
    Sumiyoshi H; Matsushita A; Nakamura Y; Yamahatsu K; Katsuno A; Uchida E
    Gan To Kagaku Ryoho; 2014 May; 41(5):669-72. PubMed ID: 24917020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
    Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
    Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
    JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
    Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
    Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case].
    Kataoka K; Matsubara H; Urano F; Okamura S; Maeda M
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(10):1777-1784. PubMed ID: 27725467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy for pancreatic cancer].
    Kim YT
    Korean J Gastroenterol; 2008 Feb; 51(2):111-8. PubMed ID: 18349573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
    Kourie HR; Gharios J; Kattan J
    Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
    Ebata T; Hirano S; Konishi M; Uesaka K; Tsuchiya Y; Ohtsuka M; Kaneoka Y; Yamamoto M; Ambo Y; Shimizu Y; Ozawa F; Fukutomi A; Ando M; Nimura Y; Nagino M;
    Br J Surg; 2018 Feb; 105(3):192-202. PubMed ID: 29405274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of squamous cell carcinoma of the pancreas with gemcitabine].
    Bideau K; Metges JP; Bayle S; André M; Robaszkiewicz M; Lagarde N; Labat JP
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1217-20. PubMed ID: 17075482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.